Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas;Kra̧ża̧ce komórki śródbłonka, prekursory śródbłonka oraz stȩżenie VEGF i bFGF u chorych na ostre białaczki, chłoniaki i szpiczaki

Polskie Archiwum Medycyny Wewnetrznej

Volumn 113, Issue 1, 2005, Pages 27-34

  Porȩba, Małgorzata ^a   Jaźwiec, Bozena ^b   Kuliczkowski, Kazimierz ^b   Porȩba, Rafał ^b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b NONE

Author keywords

Acute leukemia; Angiogenesis; bFGF; Circulating endothelial cells; Circulating endothelial precursors; Lymphoma; Myeloma; VEGF

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; PROTEIN PRECURSOR; VASCULOTROPIN; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 2; VASCULOTROPIN A;

ACTIVATED ENDOTHELIAL CELL; ACUTE LEUKEMIA; ADULT; ANGIOGENESIS; ARTICLE; CELL ACTIVATION; CIRCULATING ENDOTHELIAL PRECURSOR; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKEMOGENESIS; LYMPHOMA; MALE; MEASUREMENT; MYELOMA; PRECURSOR; PREDICTION; PROGNOSIS; STEM CELL; AGED; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; LYMPHATIC LEUKEMIA; METABOLISM; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 17444418655     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fennie C., Cheng J., Dowbenko D., Young P., Lasky L.A.: CD34+ endothelial cell lines derived from murine yolk sac induce the proliferation and differentiation of yolk sac CD34+ hematopoietic progenitors. Blood, 1995, 86, 4454.
2. Gehling U., Ergun S., Schumacher U. i wsp.: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 2000, 95, 3106.
3. Peichev M., Naiyer A.J., Pereira D. i wsp.: Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood, 2000 95, 952.
4. Yin A.H., Miraglia S., Zanjani E.D. i wsp.: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood, 1997, 90, 5002.
5. Wuchter C., Ratei R., Spahn G. i wsp.: Impact of CD133(AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001, 86, 154.
6. Mutunga M., Fulton B., Bullock R. i wsp.: Circulating endothelial cells in patients with septic shock. Am. J. Respir. Crit. Care Med., 2001, 163, 195.
7. Mutin M., Canavy I., Blann A., Bory M., Sampol J., Dignat-George F.: Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood, 1999, 93, 2951.
8. Shintani S., Murohara T., Ikeda H. i wsp.: Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation, 2001, 103, 2776.
9. Mancuso P., Burlini A., Pruneri G., Goldhirsch A., Martinelli G., Bertolini F.: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 2001, 97, 3658.
10. Monestiroli S., Mancuso P., Burlini A. i wsp.: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res., 2001, 61, 4341.
11. Padro T., Ruiz S., Bieker R. i wsp.: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood, 2000, 95, 2637.
12. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L., Dammacco F.: Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur. J. Haematol., 1996, 56, 45.
13. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., Dammacco F.: Bone marrow angiogenesis and progression in multiple myeloma. Br. J. Haematol., 1994, 87, 503.
14. Chiarugi V., Magnelli L., Cinelli M., Ruggiero M.: Oncogenes, p53, and tumor angiogenesis. J. Cancer Res. Clin. Oncol., 1998, 124, 523.
15. Asahara T., Bauters C., Zheng L.P. i wsp.: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation, 1995, 92, (suppl. 9), II 365.
16. Miller D.W., Graulich W., Karges B. i wsp.:. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int. J. Cancer, 1999, 81, 568.
17. Beereport L. V., Mehra N., Vermaat J.S.P., Zonnenberg B.A., Gebbing M.F.G.B., Voest E.E.: Increased leves of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol., 15, 2004, 139.
18. Bertolini F., Paul S., Mancuso P. i wsp.: Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res., 2003, 63, 4342.
19. Salven P., Orpana A., Joensuu H.: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res., 1999, 5, 487.
20. Glenjen N., Mosevoll K.A., Bruserud O.: Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int. J. Cancer, 2002, 101, 86.